UNITED THERAPEUTICS Corp 4

Martine A. Rothblatt (Chairperson & CEO) exercised 9,500 options and sold 9,260 United Therapeutics common shares held via a trust in 10b5‑1 plan trades on 2026-07-21.

On July 21, 2026, United Therapeutics Corporation Chairperson & CEO Martine A. Rothblatt, through a trust, exercised 9,500 stock options at an exercise price of $135.42 per share, acquiring 9,500 shares of common stock, and on the same day sold 9,260 of those shares in a series of open‑market transactions at weighted average prices between approximately $524.37 and $536.37 per share pursuant to a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025. The gross sale proceeds from the 9,260 shares totaled roughly $4.9–$5.0 million, while the intrinsic gain relative to the option strike price was materially higher, and following these transactions the trust and related family trusts continued to hold over 300,000 shares of United Therapeutics common stock and additional derivative awards, reflecting an ongoing, but modestly reduced, indirect economic interest.

Filing Facts

CIK

1082554

Ticker

UTHR

Form

4

Source Type

fda

Accession

0001106578-26-000103

Alert Tier

7